GeneDx Holdings Statistics

Total Valuation

GeneDx Holdings has a market cap or net worth of $1.94 billion. The enterprise value is $1.88 billion.

Market Cap	1.94B
Enterprise Value	1.88B

Important Dates

The next confirmed earnings date is Monday, May 4, 2026, after market close.

Earnings Date	May 4, 2026
Ex-Dividend Date	n/a

Share Statistics

GeneDx Holdings has 29.29 million shares outstanding. The number of shares has increased by 6.51% in one year.

Current Share Class	29.29M
Shares Outstanding	29.29M
Shares Change (YoY)	+6.51%
Shares Change (QoQ)	+0.88%
Owned by Insiders (%)	1.71%
Owned by Institutions (%)	90.10%
Float	20.85M

Valuation Ratios

PE Ratio	n/a
Forward PE	72.47
PS Ratio	4.53
Forward PS	3.48
PB Ratio	6.27
P/TBV Ratio	15.34
P/FCF Ratio	135.68
P/OCF Ratio	58.15
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 148.36, with an EV/FCF ratio of 131.61.

EV / Earnings	n/a
EV / Sales	4.39
EV / EBITDA	148.36
EV / EBIT	n/a
EV / FCF	131.61

Financial Position

The company has a current ratio of 2.46, with a Debt / Equity ratio of 0.37.

Current Ratio	2.46
Quick Ratio	2.26
Debt / Equity	0.37
Debt / EBITDA	5.46
Debt / FCF	7.93
Interest Coverage	-4.60

Financial Efficiency

Return on equity (ROE) is -7.60% and return on invested capital (ROIC) is -4.67%.

Return on Equity (ROE)	-7.60%
Return on Assets (ROA)	-1.55%
Return on Invested Capital (ROIC)	-4.67%
Return on Capital Employed (ROCE)	-2.81%
Weighted Average Cost of Capital (WACC)	15.50%
Revenue Per Employee	$328,876
Profits Per Employee	-$16,170
Employee Count	1,300
Asset Turnover	0.91
Inventory Turnover	10.52

Taxes

Income Tax	-116,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -40.48% in the last 52 weeks. The beta is 2.19, so GeneDx Holdings's price volatility has been higher than the market average.

Beta (5Y)	2.19
52-Week Price Change	-40.48%
50-Day Moving Average	73.09
200-Day Moving Average	109.34
Relative Strength Index (RSI)	46.00
Average Volume (20 Days)	600,343

Short Selling Information

The latest short interest is 3.96 million, so 13.53% of the outstanding shares have been sold short.

Short Interest	3.96M
Short Previous Month	3.94M
Short % of Shares Out	13.53%
Short % of Float	19.00%
Short Ratio (days to cover)	5.60

Income Statement

In the last 12 months, GeneDx Holdings had revenue of $427.54 million and -$21.02 million in losses. Loss per share was -$0.73.

Revenue	427.54M
Gross Profit	298.18M
Operating Income	-11.67M
Pretax Income	-21.14M
Net Income	-21.02M
EBITDA	12.65M
EBIT	-11.67M
Loss Per Share	-$0.73

Full Income Statement

Balance Sheet

The company has $171.28 million in cash and $113.17 million in debt, giving a net cash position of $58.11 million or $1.98 per share.

Cash & Cash Equivalents	171.28M
Total Debt	113.17M
Net Cash	58.11M
Net Cash Per Share	$1.98
Equity (Book Value)	308.18M
Book Value Per Share	10.54
Working Capital	159.38M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $33.28 million and capital expenditures -$19.02 million, giving a free cash flow of $14.26 million.

Operating Cash Flow	33.28M
Capital Expenditures	-19.02M
Depreciation & Amortization	24.32M
Net Borrowing	-3.66M
Free Cash Flow	14.26M
FCF Per Share	$0.49

Full Cash Flow Statement

Margins

Gross margin is 69.74%, with operating and profit margins of -2.73% and -4.92%.

Gross Margin	69.74%
Operating Margin	-2.73%
Pretax Margin	-4.94%
Profit Margin	-4.92%
EBITDA Margin	2.96%
EBIT Margin	-2.73%
FCF Margin	3.34%

Dividends & Yields

GeneDx Holdings does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.51%
Shareholder Yield	-6.51%
Earnings Yield	-1.09%
FCF Yield	0.74%

Analyst Forecast

The average price target for GeneDx Holdings is $120.71, which is 82.70% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$120.71
Price Target Difference	82.70%
Analyst Consensus	Strong Buy
Analyst Count	7
Revenue Growth Forecast (5Y)	19.72%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on May 4, 2023. It was a reverse split with a ratio of 1:33.

Last Split Date	May 4, 2023
Split Type	Reverse
Split Ratio	1:33

Scores

GeneDx Holdings has an Altman Z-Score of 5.64 and a Piotroski F-Score of 5.

Altman Z-Score	5.64
Piotroski F-Score	5